[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340824-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340824-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multiple-machine-learning-tools-identifying-prognostic-biomarkers-for-acute-myeloid-leukemia-research-article","Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid Leukemia - Research article","","Acute Myeloid Leukemia (AML) has a relatively low post-treatment survival rate, creating an urgent need for biomarkers that can improve survival prognosis. The study applies multiple machine-learning models (including LASSO, SVM-RFE, Random Forest, and XGBoost and related functions) to screen AML-linked genes. Using TCGA pan-cancer analysis, it evaluates correlations between key genes and AML or other cancers. Diagnostic and prognostic relevance is further verified across different datasets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multiple-machine-learning-tools-identifying-prognostic-biomarkers-for-acute-myeloid-leukemia-research-article/340824/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multiple-machine-learning-tools-identifying-prognostic-biomarkers-for-acute-myeloid-leukemia-research-article/340824.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are prognostic biomarkers urgently needed in AML?","Question",{"text":63,"@type":64},"AML generally has a low survival rate after treatment, and improved biomarkers are needed to better predict patient prognosis and support deeper understanding of disease mechanisms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which machine-learning models were used to identify key AML-associated genes?",{"text":68,"@type":64},"The study used LASSO, SVM-RFE, Random Forest, XGBoost, and additional functional sets (lrFuncs, IdaProfile, caretFuncs, nbFuncs) to screen genes closely associated with AML.",{"name":70,"@type":61,"acceptedAnswer":71},"What key genes were selected and what roles did they show?",{"text":72,"@type":64},"After intersecting results across methods, DNM1, MEIS1, and SUSD3 were selected. Pan-cancer analysis indicated higher expression of MEIS1 and DNM1 in AML; MEIS1 and SUSD3 were potential AML risk factors, while DNM1 was a potential protective factor.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340824,1790193280,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Cheng et al. BMC Medical Informatics and Decision Making (2024) 24:2  \n[https://doi.org/10.1186/s12911-023-02408-9](https://doi.org/10.1186/s12911-023-02408-9)  \nBMC Medical Informatics and Decision Making  \nRESEARCH Open Access  \nMultiple machine-learning tools identifying prognostic biomarkers for acute Myeloid Leukemia  \nYujing Cheng 1, Xin Yang 1, Ying Wang 1, Qi Li 1, Wanlu Chen 1, Run Dai 1 and Chan Zhang 1*  \nAbstract  \nBackground Acute Myeloid Leukemia (AML) generally has a relatively low survival rate after treatment. There is an urgent need to find new biomarkers that may improve the survival prognosis of patients. Machine-learning tools are more and more widely used in the screening of biomarkers.  \nMethods Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine-Recursive Feature Elimination (SVM-RFE), Random Forest (RF), eXtreme Gradient Boosting (XGBoost), lrFuncs, IdaProfile, caretFuncs, and nbFuncs models were used to screen key genes closely associated with AML. Then, based on the Cancer Genome Atlas (TCGA), pan-cancer analysis was performed to determine the correlation between important genes and AML or other cancers. Finally, the diagnostic value of important genes for AML was verified in different data sets.  \nResults The survival analysis results of the training set showed 26 genes with survival differences. After the intersection of the results of each machine learning method, DNM1, MEIS1, and SUSD3 were selected as key genes for subsequent analysis. The results of the pan-cancer analysis showed that MEIS1 and DNM1 were significantly highly expressed in AML; MEIS1 and SUSD3 are potential risk factors for the prognosis of AML, and DNM1 is a potential protective factor. Three key genes were significantly associated with AML immune subtypes and multiple immune checkpoints in AML. The results of the verification analysis show that DNM1, MEIS1, and SUSD3 have potential diagnostic value for AML.  \nConclusion Multiple machine learning methods identified DNM1, MEIS1, and SUSD3 can be regarded as prognostic biomarkers for AML.  \nKeywords Acute Myeloid Leukemia, Machine learning methods, LASSO, RF, SVM-RFE, eXtreme gradient boosting, Pan-cancer  \n*Correspondence:  \nChan Zhang  \n[zhangchanyzt@163.com](zhangchanyzt@163.com)  \n1Department of blood transfusion, The First People’s Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, 650034 Kunming, Yunnan, China  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nCheng et al. BMC Medical Informatics and Decision Making (2024) 24:2 Page 2 of 15  \nBackgrounds  \nAcute myeloid leukemia (AML) is a malignant bone marrow disease characterized by clonal expansion and differentiation arrest of bone marrow progenitor cells. Most AML cases still have no clear etiology [1]. AML is the most com","cbCaitfpyjZBBZb3","https://ap.wps.com/l/cbCaitfpyjZBBZb3","pdf",9875533,15,"English","# Abstract\n# Background\n## AML overview and clinical need\n## Databases and machine-learning risk models\n# Methods\n## Gene screening with multiple models\n## TCGA pan-cancer correlation analysis\n## Validation across datasets\n# Results\n## Survival differences and key gene selection\n## Pan-cancer expression and risk/protective roles\n## Immune subtype and checkpoint associations\n## Diagnostic verification\n# Conclusion","[{\"question\":\"Why are prognostic biomarkers urgently needed in AML?\",\"answer\":\"AML generally has a low survival rate after treatment, and improved biomarkers are needed to better predict patient prognosis and support deeper understanding of disease mechanisms.\"},{\"question\":\"Which machine-learning models were used to identify key AML-associated genes?\",\"answer\":\"The study used LASSO, SVM-RFE, Random Forest, XGBoost, and additional functional sets (lrFuncs, IdaProfile, caretFuncs, nbFuncs) to screen genes closely associated with AML.\"},{\"question\":\"What key genes were selected and what roles did they show?\",\"answer\":\"After intersecting results across methods, DNM1, MEIS1, and SUSD3 were selected. Pan-cancer analysis indicated higher expression of MEIS1 and DNM1 in AML; MEIS1 and SUSD3 were potential AML risk factors, while DNM1 was a potential protective factor.\"}]","Multiple machine-learning tools identifying prognostic biomarkers for acute Myeloid Leukemia - Research article | PDF",1790039061,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07bd63bfd6b00a5ac955a7cd49b474a6.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37dfce8b6d26601b8155ad5f4e340543.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/550a8268eddc860ceb676c9f540329b5.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69a2314b955df4f8160919a9f1723fbf.webp",980,1306]